COX-2 Woes’ Impact On Wholesaler Revenues Are Minimal, ABC Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
AmerisourceBergen would lose about 1% of revenues if all COX-2 inhibitors were withdrawn from the market, CEO David Yost said Jan. 25
You may also be interested in...
AmerisourceBergen Opens Its Books To Manufacturers In Contract Talks
"Manufacturers have lost track of the real value" wholesalers add to the channel, CEO Yost says. McKesson and Cardinal may also offer transparency in fee-for-service negotiations, Yost speculates.
COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda
FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.